Abstract:Abstract Vascular endothelial growth inhibitor (VEGI, also known as TNFSF15) is an anti-angiogenic cytokine found to be associated with tumour-related vasculature in certain maligancies. Three isoforms, VEGI 251, VEGI192, and VEGI174, have been identified, all sharing a common extracellular domain of 151 C-terminal amino acid sequence critical for biological activity of all three isoforms. Previous studies showed tumor inhibitory effect of truncated recombinant VEGI proteins in breast and colorectal cancer xenograft models, however, the antitumor activity of the full length VEGI molecules have not been well characterized in other malignancies, including kidney neoplasm. The objective of the present study was set to evaluate biological impact of forced expression of full length VEGI-174 in a renal cell carcinoma (RCC) cell line, 786-O, and in 786-O derived xenograft models. We found that Increased VEGI-174 expression in 786-O cells did not affect cell growth and apoptosis in vitro, but did reduce cell adhesion and the ability of endothelial cells to form capillary-like structures in co-culture. Subcutaneous xenograft models were successfully established using the 786-O RCC cells with or without forced expression of VEGI-174. Significantly reduced tumor volume, accompanied by reduced tumor microvessel density and decreased Ki67 and VEGFR2 expression, was observed in animals injected with VEGI-174 transfected 786-O cells compared to those in the control groups. Our results demonstrated that increased expression of full length VEGI-174 in RCC 786-O cells resulted in significant reduction in tumor volume most likely via angiogenic inhibition rather than on tumor growth per se. Despite the lack of antitumor effect of full length VEGI174 in some xenograft tumor models in other studies, our results suggest that antitumor effect of the full length VEGI-174 may be cancer type specific, and VEGI-174 may still be a valuable candidate toward angiogenesis based cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1356. doi:1538-7445.AM2012-1356

The Structure-Function Relationship Analysis of VEGI: Y111 is an Important Residue in Biological Activity

Effect of N-Terminal Deletion on Biological Activity of Vascular Endothelial Cell Growth Inhibitor

Structure and Function of Vascular Endothelial Growth Factor and Its Related Proteins

Vascular Endothelial Growth Inhibitor in Human Cancer (Review)

Defining Civil Defense in the Information Age

A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics

Structure-activity relationship study of a small cyclic peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor interaction with Neuropilin-1

VEGI 174 Protein and Its Functional Domain Peptides Exert Antitumour Effects on Renal Cell Carcinoma

Mutation of the Conserved G66 Residue in GS Region Decreased Structural Stability and Activity of Arginine Kinase

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Characterization of Vascular Endothelial Growth Factor'S Effect on the Activation of Protein Kinase C, Its Isoforms, and Endothelial Cell Growth

T273 Plays an Important Role in the Activity and Structural Stability of Arginine Kinase.

VEGF165 Modulates Proliferation, Adhesion, Migration and Differentiation of Cultured Human Outer Root Sheath Cells from Central Hair Follicle Epithelium Through VEGFR-2 Activation in Vitro

Comprehensive structural and functional analysis of hVEGFR1: Insights into phosphorylation, molecular interactions, and potential inhibitors through docking and dynamics simulations

Vitronectin Regulation of Vascular Endothelial Growth Factor-Mediated Angiogenesis

Structural insights into molecular-targeting helix-loop-helix peptide against vascular endothelial growth factor-A

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

VEGFA, B, C: Implications of the C-Terminal Sequence Variations for the Interaction with Neuropilins

Structure-activity relationship studies and biological properties evaluation of peptidic NRP-1 ligands: Investigation of N-terminal cysteine importance